| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Prashanth Rawla | Q57002933 |
| Andreas V Hadjinicolaou | Q90333939 | ||
| P2093 | author name string | Adam Barsouk | |
| Alexander Barsouk | |||
| P2860 | cites work | Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials | Q92249245 |
| Revisiting immune escape in colorectal cancer in the era of immunotherapy | Q92311646 | ||
| Targeted antibody and cytokine cancer immunotherapies through collagen affinity | Q93010833 | ||
| The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Dendritic cell-based cancer immunotherapy for colorectal cancer | Q26751339 | ||
| Peptide Vaccine Therapy in Colorectal Cancer | Q26830336 | ||
| Value of bevacizumab in treatment of colorectal cancer: A meta-analysis | Q26849789 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| A genetic model for colorectal tumorigenesis | Q27860582 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer | Q28248065 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Systematic review of microsatellite instability and colorectal cancer prognosis | Q28303189 | ||
| PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration | Q28378001 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials | Q41458113 | ||
| SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer | Q41733204 | ||
| Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer | Q46128012 | ||
| Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer | Q46233566 | ||
| A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. | Q46454840 | ||
| Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer | Q46658474 | ||
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer | Q46662707 | ||
| A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer | Q46699227 | ||
| Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | Q49887005 | ||
| Nivolumab plus ipilimumab in metastatic colorectal cancer | Q50207714 | ||
| Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. | Q50876217 | ||
| DNA mismatch repair in cancer. | Q52580154 | ||
| Updates on immunotherapy for colorectal cancer. | Q52643529 | ||
| A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead. | Q53384598 | ||
| Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. | Q54960920 | ||
| Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. | Q54962247 | ||
| Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. | Q55044963 | ||
| Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. | Q30317446 | ||
| Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates | Q30538531 | ||
| Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. | Q33228030 | ||
| Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer | Q33389767 | ||
| Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. | Q33828559 | ||
| Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. | Q33885727 | ||
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 | ||
| Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy | Q34187436 | ||
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. | Q34492429 | ||
| Impact of EGFR expression on colorectal cancer patient prognosis and survival | Q34553435 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study | Q34583973 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | Q34642136 | ||
| Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial | Q34656044 | ||
| Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. | Q34658519 | ||
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color | Q34660907 | ||
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial | Q34663697 | ||
| Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl | Q34669325 | ||
| Mature Results of a Prospective Randomized Trial Comparing 5-Flourouracil with Leucovorin to 5-Flourouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer- The Israel Cooperative Oncology Group (ICOG) Study | Q34751755 | ||
| The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy | Q34970884 | ||
| Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab | Q35705200 | ||
| Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer | Q35968018 | ||
| Epidermal growth factor receptor targeting in cancer | Q36557269 | ||
| A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. | Q36616783 | ||
| Anti-CD73 in cancer immunotherapy: awakening new opportunities. | Q36709157 | ||
| A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. | Q37266006 | ||
| Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer | Q37421439 | ||
| Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment | Q38755813 | ||
| MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade | Q38788877 | ||
| Metabolite and Microbiome Interplay in Cancer Immunotherapy | Q38800832 | ||
| Global patterns and trends in colorectal cancer incidence and mortality. | Q38915351 | ||
| Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial | Q39980841 | ||
| Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment | Q39993891 | ||
| Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. | Q55046482 | ||
| Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. | Q55130826 | ||
| Immunotherapy in colorectal cancer: for the select few or all? | Q55333223 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study | Q57152185 | ||
| Current status of immunotherapy in metastatic colorectal cancer | Q59350349 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Every step of the way: integrins in cancer progression and metastasis | Q60340345 | ||
| Gut Microbiota and Cancer: From Pathogenesis to Therapy | Q61806850 | ||
| Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival | Q74453121 | ||
| Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) | Q82294729 | ||
| Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study | Q83801480 | ||
| Duration of Adjuvant Chemotherapy for Stage III Colon Cancer | Q88202109 | ||
| Immunosuppressive enzymes in the tumor microenvironment | Q88731021 | ||
| Genetic and epigenetic alterations of colorectal cancer | Q90842099 | ||
| Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib | Q91241914 | ||
| The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy | Q91520697 | ||
| Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management | Q91546708 | ||
| Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy | Q91951567 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P921 | main subject | metastatic colon cancer | Q108566365 |
| colorectal cancer | Q188874 | ||
| immunotherapy | Q1427096 | ||
| P577 | publication date | 2019-07-30 | |
| P1433 | published in | Medical Sciences | Q27725458 |
| P1476 | title | Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer | |
| P478 | volume | 7 |
| Q89597699 | A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer |
| Q92642710 | Long Non-Coding RNA (lncRNA) BMP/OP-Responsive Gene (BORG) Promotes Development of Chemoresistance of Colorectal Cancer Cells to Carboplatin |
| Q91805763 | STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability |
Search more.